Amsterdam UMC
Amsterdam, Netherlands
NCT Number: NCT07799298
Rationale: During left pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), routine en-bloc splenectomy is performed to achieve complete nodal clearance of the splenic hilum. However, evidence that splenectomy improves survival is lacking, while splenectomy may increase postoperative morbidity and has lifelong consequences related to loss of splenic function. Spleen-preserving left pancreatectomy (SPLP) may be a safe alternative, but high-quality evidence is lacking.
Objective: To compare SPLP with left pancreatectomy with splenectomy (LPS) regarding overall survival and major postoperative morbidity in patients with resectable or borderline resectable PDAC.
Study design: An international, randomized, controlled, multicenter, non-inferiority trial.
Study population: Two groups of 180 patients (360 in total) with proven or suspected resectable or borderline resectable PDAC requiring left pancreatectomy.
Intervention: Spleen-preserving left pancreatectomy (SPLP)
Control: Left pancreatectomy with splenectomy (LPS)
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Amsterdam, Netherlands
Rationale: During left pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), routine en-bloc splenectomy is performed to achieve complete nodal clearance of the splenic hilum. However, there is no evidence that routine splenectomy improves survival. Splenectomy has been associated with increased postoperative morbidity, lifelong vaccination requirements, and risk of overwhelming post-splenectomy infection. In addition, lymph node metastases in the splenic hilum are uncommon (~4%), and preservation of splenic immune function is becoming increasingly important with the emergence of novel immunotherapies. Spleen-preserving left pancreatectomy (SPLP) may therefore be a safe alternative to routine splenectomy, but no randomized trials have evaluated this approach.
Objective: To compare SPLP with left pancreatectomy with splenectomy (LPS) regarding (1) overall survival over a 3-year period, assessed using restricted mean survival time (RMST), and (2) major postoperative complications within 90 days (Clavien-Dindo grade III or higher) in patients with resectable or borderline resectable PDAC.
Study design: An international randomized multicenter non-inferiority trial performed in high-volume pancreatic centers. Participating centers perform at least 15 left pancreatectomies annually, and participating surgeons have completed at least 30 SPLPs (for any indication) and 15 left pancreatectomies for PDAC. Randomization will be performed in a 1:1 ratio using a secure web-based system, stratified for receipt of neoadjuvant therapy (yes/no) and tumor location (body/neck versus tail).
Study population: Two groups of 180 patients (360 in total) with proven or suspected resectable or borderline resectable PDAC requiring left pancreatectomy.
Intervention: Spleen-preserving left pancreatectomy.
Control: Left pancreatectomy with splenectomy.
Main study parameters/endpoints: The primary endpoint is overall survival over a 3-year period, assessed using RMST. The main secondary endpoint is major postoperative morbidity within 90 days (Clavien-Dindo grade III or higher). Other secondary outcomes include quality of life, R0 resection rate, disease-free survival, time to and site of recurrence, receipt, timing and completion of adjuvant therapy, pancreas-specific and general postoperative complications, unplanned splenectomy in the SPLP group, secondary splenectomy, spleen- and asplenia-related complications, time to functional recovery, length of hospital stay, health-care resource utilization, and cost-effectiveness.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
o Patients receiving neo-adjuvant treatment can be included in the trial, if the tumor was upfront resectable or borderline-resectable before the start of neoadjuvant therapy. Patients receiving induction therapy for locally advanced pancreatic cancer (LAPC) will be excluded.
Exclusion criteria
Spleen-preserving Left Pancreatectomy
Left Pancreatectomy with Splenectomy
Time frame: Until 3-years after the day of surgery
Time frame: From the day of surgery until 90-days postoperative
Clavien-Dindo classification grade ≥3
Time frame: Day of operation
Time frame: Day of surgery until 90-days postoperative
Time frame: When pathology report available postoperative
Time frame: Until 5-years postoperative
Time frame: Until 5-years postoperative
Time frame: Preoperative until 5 years postoperative
EQ-5D-5L; Health states are converted into an index value using the prespecified value set. A value of 1 represents full health, 0 represents a health state equivalent to death, and negative values represent health states considered worse than death. Higher values indicate a better outcome. The possible minimum value is [insert minimum for the selected value set] and the maximum is 1.
Time frame: Preoperatively until 5 years postoperatively
QLQ-C30; Scale and single-item scores range from 0 to 100. Higher scores on the functional scales and global health status/quality-of-life scale indicate better functioning or quality of life, whereas higher scores on the symptom scales indicate more severe symptoms and therefore a worse outcome.
Time frame: Preoperatively until 5 years postoperative
PAN26; Scale and single-item scores range from 0 to 100. Higher scores on symptom scales indicate more severe symptoms and therefore a worse outcome, whereas higher scores on the satisfaction with health care and sexuality functional scales indicate better functioning and therefore a better outcome.
Time frame: Day of operation
Time frame: Day of surgery
Conversion; yes/no, emergency of non emergency
Time frame: Day of surgery
Pancreatic duct size; mm
Time frame: Day of surgery
Time frame: Day of surgery
Time frame: Day of surgery
Time frame: Day of surgery
Time frame: Day of surgery
Time frame: Day of surgery
Time frame: Day of surgery
Time frame: Day of surgery until 90 days postoperative
Time frame: When pathology report available postoperative
Time frame: When pathology report available postoperative
Time frame: When pathology report available postoperative
Time frame: When pathology available postoperative
Time frame: When pathology report available postoperative
Contact information is provided by the study sponsor or research team.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID): an International Randomized Controlled Trial
Acronym: SPLENDID RCT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07342231
Adenocarcinoma Pancreas, Digestive System Diseases
Mumbai, Maharashtra, India
View Trial DetailsNCT06938906
Digestive System Diseases, Digestive System Neoplasms
Tainan, Taiwan
View Trial DetailsNCT07796997
Digestive System Diseases, Digestive System Neoplasms
Chicago, Illinois, United States
View Trial DetailsNCT07796906
Anxiety, Anxiety Disorders
Tianjin, Tianjin Municipality, China
View Trial Details